LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

Central to the lawsuit is the claim that the company's "optimistic forecasts" about CagriSema's effectiveness were unfounded. The suit also contends that the study's "flexible protocol," which ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

LONDON/SAN FRANCISCO (Reuters) – Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...